ISC 2018: COMPASS Supports First-Line Aspiration With Penumbra's System
Results of the COMPASS trial showed that Penumbra's aspiration system is non-inferior to stent-retrievers as a first-line therapy to treat acute ischemic stroke. COMPASS was one of several important device trials featured at the presented at the International Stroke Conference held in Los Angeles.
You may also be interested in...
Riptide complements Medtronic's Solitaire stent retriever revascularization device for the treatment of acute ischemic stroke. The company began rolling out Riptide at this year's International Stroke Conference, which also featured the presentation of important clinical data supporting aspiration as a first-line therapy for stroke.
Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.
The US FDA approved fewer novel devices in 2019 than in 2018, despite a slight increase in original PMA approvals. De novo clearances were down significantly after four straight years of increases, while panel-track PMA supplements and 510(k) clearances also declined from the 2018 totals.